According to the website of the National Medical Products Administration, on March 19th, Huang Guo, a member of the Party Group and Deputy Director of the National Medical Products Administration, led a team to the Beijing Institute of Life Sciences to investigate the research and development of new mechanisms and new target drugs, and held a symposium to listen to expert opinions and suggestions. The meeting pointed out that the current development trend of innovative drugs in China continues to improve, with the foundation and potential to steadily improve and upgrade, and achieve high-level breakthroughs. The National Medical Products Administration will further focus on source innovation, continue to deepen the reform of the review and approval system, and support breakthroughs from scratch. We need to establish a tracking mechanism for major innovation project research and development, establish a sound communication and exchange service mechanism for early research and development stages, strengthen regulatory scientific research and application in relevant fields, improve the quality and efficiency of services for major innovation projects, and better meet the public's medication needs. (New Society)